- Accu-Chek ® Guide Me glucose meter to be paired with BlueStar ® in Japan, which is being jointly developed by Astellas and Welldoc - - Initiation of clinical trial planned for fiscal year 2023 - ...

Roche Diabetes Care’s senior vice president and general manager lists ways the company works with pharmacies to support diabetes patients when and where they need it. Diabetes never quits. Every day, ...

History: Roche Diagnostics Corp. is a division of Roche, the world’s largest biotech company and a global pioneer in pharmaceuticals and diagnostics. The Indianapolis division began as locally based ...

In March, Roche received FDA clearance for its Accu-Chek Connect companion app, and, less than a month later, issued a recall of that app. App recalls, which are becoming more common as more and more ...

Diabetes and insulin management software company Glytec and pharmaceutical firm Roche are teaming up to allow the use of Glytec's software in connection with Roche's point-of-care smart-device ...

BASEL, Switzerland, Oct 2 (Reuters) - Swiss pharmaceuticals company Roche Holding AG named a new head to its diagnostics division on Tuesday and boosted the standing of its diabetes activities within ...

Roche Diabetes Care recalled its Accu-Chek Connect diabetes management app over software issues, according to an FDA safety alert issued Feb. 15. 1. Certain iOS and Android versions of the app contain ...

Sanofi and Roche have joined forces in France, teaming up to drive adoption of a connected add-on for disposable insulin pens. The partners will jointly develop a scientific program for physicians and ...

Roche Diabetes Care’s Insulin Delivery Systems unit issued a recall for one of its infusion sets while it tries to work out the kinks — literally. There’s a possibility that its Accu-Chek FlexLink ...

Roche signed a collaboration agreement with telemedicine solutions provider Care Innovations, the Swiss pharmaceutical company confirmed June 25. Here are four notes on the agreement: 1. Care ...

TOKYO and COLUMBIA, Md., March 28, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that it has entered into an agreement ...